h-VIOS2 h-VIOS2 containing two perfused vascularized hydrogels. Within this chip’s footprint, any vasculature can be created. Taci Pereira Taci Pereira named CEO of Systemic Bio. New company will leverage 3D Systems’ recent breakthroughs in bioprinting of vascularized human organs and tissues to accelerate new drug development, reduce costs, and ultimately reduce or eliminate the need for animal testingUnique bioprinted organ-on-a-chip platform, h-VIOS™, created using hydrogels to produce comple
United Therapeutics Corporation (UTHR) stock has jumped this year, gaining 10% so far.
Amendment expands program from a singular focus on the bioprinting of human lung scaffolds to the development and demonstration of two additional human organsAmendment will become effective upon closing of 3D Systems’ acquisition of Volumetric Biotechnologies, Inc., which was announced earlier todayExpanded program leverages progress made on the bioprinting of lung scaffolds for application across multiple human organs using the jointly developed technology platformProgram builds upon a foundati